Article

Free Access

In Vitro Susceptibilities of Candida spp. to Panomycocin, a Novel Exo-β-1,3-Glucanase Isolated from Pichia anomala NCYC 434

Corresponding Author

Fatih İzgü

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Address correspondence to Dr. Fatih İzgü, Department of Biological Sciences, Middle East Technical University, 06531, Ankara, Turkey. Fax: +90-312-2107976. E-mail: [email protected]Search for more papers by this author

Demet Altınbay,

Demet Altınbay

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Search for more papers by this author

Akif Emre Türeli,

Akif Emre Türeli

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Search for more papers by this author

Fatih İzgü,

Corresponding Author

Fatih İzgü

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Demet Altınbay,

Demet Altınbay

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Search for more papers by this author

Akif Emre Türeli,

Akif Emre Türeli

Department of Biological Sciences, Middle East Technical University, 06531 Ankara, Turkey

Search for more papers by this author

First published: 14 November 2013

https://doi.org/10.1111/j.1348-0421.2007.tb03975.x

Citations: 27

Share a link

Email
Wechat
Bluesky

Abstract

Panomycocin, the killer toxin of Pichia anomala NCYC 434 (K5), is a 49 kDa monomeric glycoprotein with exo-β–1,3-glucanase activity (patent pending). In this study we evaluated the in vitro activity of panomycocin against a panel of 109 human isolates of seven different pathogenic Candida spp. using microdilution and time-kill methods. Panomycocin was most active against C. tropicalis, C. pseudotropicalis and C. glabrata with MIC₉₀ values of 1 μg/ml. It displayed significant activity against C. albicans and C parapsilosis with MIC₉₀ values of 4 and 2 μg/ml, respectively. For C. krusei, the MIC₉₀ value was 8 μg/ml. Panomycocin was fungicidal against all the tested Candida spp. The MFC values were only one or 2 dilutions higher than the MICs with the exception of C. krusei isolates with MFCs greater than or equal to 4 × MIC. Results of this study indicated that panomycocin could be considered as a natural antifungal agent against Candida infections and has significant potential for further investigation.

Abbreviations

API: analytical profile index
ATCC: American Type Culture Collection
CFU: colony forming units
CLSI: Clinical and Laboratory Standards Institute
DSMZ: German Collection of Microorganisms and Cell Cultures
K+: killer phenotype
MFC: the minimum fungicidal concentration
MIC: minimum inhibitory concentration
MOPS: 3-N-morpholino-propanesulfonic acid
NCYC: National Collection of Yeast Cultures
RPMI: Roswell Park Memorial Institute
SDA: Sabouraud dextrose agar
TUBITAK: Scientific and Technological Research Council of Turkey.

References

1Bartizal, C., and Odds, F.C. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47: 2100–2107.
10.1128/AAC.47.7.2100-2107.2003
CAS PubMed Web of Science® Google Scholar
2Bevan, E.A., and Makower, M. 1963. The physiological basis of the killer character in yeast. Proc. 11th Int. Cong. Gene 1: 202–203.
Google Scholar
3Bobek, L.A., and Situ, H. 2003. MUC 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob. Agents Chemother. 47: 643–652.
10.1128/AAC.47.2.643-652.2003
CAS PubMed Web of Science® Google Scholar
4Bradford, M.A. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254.
10.1016/0003-2697(76)90527-3
CAS PubMed Web of Science® Google Scholar
5Canton, E., Peman, J., Gobernado, M., Viudes, A., and Espinel-Ingroff, A. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48: 2477–2482.
10.1128/AAC.48.7.2477-2482.2004
CAS PubMed Web of Science® Google Scholar
6 Clinical and Laboratory Standards Institute. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A, Clinical and Laboratory Standards Institute, Wayne, Pa.
Google Scholar
7Dereinski, S.C., and Stevens, D.A. 2003. Caspofungin. Clin. Infect. Dis. 36: 1445–1457.
10.1086/375080
PubMed Web of Science® Google Scholar
8Devkatte, A.N., Zore, G.B., and Karuppayil, S.M. 2005. Potential of plant oils as inhibitors of Candida albicans growth. FEMS Yeast Res. 5: 867–873.
10.1016/j.femsyr.2005.02.003
CAS PubMed Web of Science® Google Scholar
9Disney, M.D., Constantine, G.H., and Douglas, H.T. 2002. Uptake and antifungal activity of oligonucleotides in Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 100: 1530–1534.
10.1073/pnas.0337462100
CAS PubMed Web of Science® Google Scholar
10Espinol-Ingroff, A., Warnock, D.W., Vazquez, J.A., and Arthington-Skaggs, B.A. 2000. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med. Mycocl. Suppl. 1: 293–304.
Google Scholar
11Hacek, D.M., Noskin, G.A., Trakas, K., and Peterson, L.R. 1995. Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J. Clin. Microbiol. 33: 1884–1889.
CAS PubMed Web of Science® Google Scholar
12Hazen, K.C. 1995. New and emerging yeast pathogens. Clin. Microbial Rev. 8: 462–478.
10.1128/CMR.8.4.462
CAS PubMed Web of Science® Google Scholar
13Hossain, A.G., and Ghannoum, M.A. 2001. New developments in chemotherapy for non-invasive fungal infections. Expert Opin. Invest. Drug. 10: 1501–1511.
10.1517/13543784.10.8.1501
CAS PubMed Web of Science® Google Scholar
14İzgü, F., and Altınbay, D. 2004. Isolation and characterization of the K5-type yeast killer protein and its homology with an exo-β-1,3-glucanase. Biosci. Biotechnol. Biochem. 68: 685–693.
10.1271/bbb.68.685
CAS PubMed Web of Science® Google Scholar
15İzgu, F., Altınbay, D., and Sertkaya, A. 2005. Enzymic activity of the K5-type yeast killer toxin and its characterization. Biosci. Biotechnol. Biochem. 69: 2200–2206.
10.1271/bbb.69.2200
CAS PubMed Web of Science® Google Scholar
16İzgu, F., Altınbay, D., and Türeli, E.A. 2007. In vitro activity of panomycocin, a novel exo-β-1,3 glucanase isolated from Pichia anomala NCYC 434, against dermatophytes. Mycoses 50: 31–34.
10.1111/j.1439-0507.2006.01303.x
PubMed Web of Science® Google Scholar
17Marr, K.A., Rustad, T.R., Rex, J.H., and White, T.C. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43: 1383–1386.
CAS PubMed Web of Science® Google Scholar
18Panda, D., Rathinasamy, K., Manas, K.S., and Wilson, L. 2005. From the cover: kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc. Natl. Acad. Sci. U.S.A. 102: 9548–9553.
10.1073/pnas.0501821102
CAS Web of Science® Google Scholar
19Pfaller, M.A., Messer, S.A., Boyken, L., Huynh, H., Hollis, R.J., and Diekema, D.J. 2002. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using national committee for clinical laboratory standards susceptibility testing methods. Antimicrob. Agents Chemother. 46: 3518–3521.
10.1128/AAC.46.11.3518-3521.2002
CAS PubMed Web of Science® Google Scholar
20Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., and Diekema, D.J. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44: 760–763.
10.1128/JCM.44.3.760-763.2006
CAS PubMed Web of Science® Google Scholar
21Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., and Diekema, D.J. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44: 3533–3538.
10.1128/JCM.00872-06
CAS PubMed Web of Science® Google Scholar
22Pfeiffer, I., Golubev, W.I., Farlas, Z., Kucsera, J., and Golubev, N. 2004. Mycocin production in Cryptococcus aquaticus. Antonie Leeuwenhoek 86: 369–375.
10.1007/s10482-004-0888-0
CAS PubMed Web of Science® Google Scholar
23Ramani, R., and Chaurvedi, V. 2000. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob. Agents Chemother. 44: 2752–2758.
10.1128/AAC.44.10.2752-2758.2000
CAS PubMed Web of Science® Google Scholar
24Reeves, E.P., Murphy, T., Daly, P., and Kavanagh, K. 2004. Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus. J. Med. Microbiol. 53: 719–725.
10.1099/jmm.0.45626-0
CAS PubMed Web of Science® Google Scholar
25Ryder, N.S., Wagner, S., and Leitner, I. 1998. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob. Agents Chemother. 42: 1057–1061.
10.1128/AAC.42.5.1057
CAS PubMed Web of Science® Google Scholar
26Sangorrin, M.P., Zajonskovsky, I.E., and Lopez, C.A. 2001. Killer behaviour in wild wine yeasts associated with Merlot and Malbec type musts spontaneously fermented from north western Patagonia (Argentina). J. Basic Microbiol. 41: 105–113.
10.1002/1521-4028(200105)41:2<105::AID-JOBM105>3.0.CO;2-W
CAS PubMed Web of Science® Google Scholar
27Schmitt, M.J., and Breinig, F. 2002. The viral killer system in yeast: from molecular biology to application. FEMS Microbiol. Rev. 26: 257–276.
10.1111/j.1574-6976.2002.tb00614.x
CAS PubMed Web of Science® Google Scholar
28Sheehan, D.J., Hıtchcock, C.A., and Sibley, C.M. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12: 40–79.
10.1128/CMR.12.1.40
CAS PubMed Web of Science® Google Scholar
29Selitrennikoff, C.P. 2001. Antifungal proteins. Appl. Environ. Microbiol. 67: 2883–2894.
10.1128/AEM.67.7.2883-2894.2001
CAS PubMed Web of Science® Google Scholar
30Staib, F. 1999. The green colour effect (GCE) of the killer strain Cryptococcus laurentii CBS 139 on Staib agar. Mycoses 42: 103–106.
10.1046/j.1439-0507.1999.00408.x
CAS PubMed Web of Science® Google Scholar
31Takemoto, K., Yamamoto, Y., and Ueda, Y. 2006. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol. Immunol. 50: 579–586.
10.1111/j.1348-0421.2006.tb03832.x
CAS PubMed Web of Science® Google Scholar
32Venkatesan, P., Perfect, J.R., and Myers, S.A. 2005. Evaluation and management of fungal infections in immunucompromised patients. Dermatol. Ther. 18: 44–57.
10.1111/j.1529-8019.2005.05001.x
CAS PubMed Google Scholar
33Walker, G.M., McLeod, A.H., and Hodgson, V.J. 1995. Interactions between killer yeasts and pathogenic fungi. FEMS Microbiol. Lett. 127: 213–222.
10.1111/j.1574-6968.1995.tb07476.x
CAS PubMed Web of Science® Google Scholar
34Wickner, R.B. 1979. The killer double stranded RNA plasmids of yeast. Plasmid 2: 303–322.
10.1016/0147-619X(79)90015-5
CAS PubMed Web of Science® Google Scholar
35Yap, N.A., Lopes, B., Langridge, P., and Henschke, P.A. 2000. The incidence of killer activity of non-Saccharomyces yeasts towards indigenous yeast species of grape must: potential application in wine fementation. J. Appl. Microbiol. 89: 381–389.
10.1046/j.1365-2672.2000.01124.x
CAS PubMed Web of Science® Google Scholar
36Young, T.W., and Yagiu, M.A. 1978. A comparison of the killer character in different yeasts and its classification. Antonie Leewenhoek 44: 59–77.
10.1007/BF00400077
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume51, Issue9

September 2007

Pages 797-803

In Vitro Susceptibilities of Candida spp. to Panomycocin, a Novel Exo-β-1,3-Glucanase Isolated from Pichia anomala NCYC 434

Abstract

Abbreviations

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

In Vitro Susceptibilities of Candida spp. to Panomycocin, a Novel Exo-β-1,3-Glucanase Isolated from Pichia anomala NCYC 434

Abstract

Abbreviations

References

Citing Literature

References

Related

Information